8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Jan 12, 2026·SEC
Geron Corporation(GERN)Earnings, Financials & Key Ratios
GERN•NASDAQ
$1.56
$1000M mkt cap·Price updated May 6, 2026
AboutGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Show more
- Revenue$184M+138.8%
- EBITDA-$53M+69.5%
- Net Income-$86M+50.9%
- EPS (Diluted)-0.13+51.9%
- Gross Margin97.42%-1.0%
- EBITDA Margin-28.62%+87.2%
- Operating Margin-29.28%+87.0%
- Net Margin-46.65%+79.4%
- ROE-33.89%+48.7%
- ROIC-11.2%+74.8%
- Debt/Equity1.11+156.5%
- Interest Coverage-1.63+80.7%
GERN Key Insights
Geron Corporation (GERN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 273.5%
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GERN Price & Volume
Geron Corporation (GERN) stock price & volume — 10-year historical chart
Loading chart...
GERN Growth Metrics
Geron Corporation (GERN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years17.59%
5 Years273.49%
3 Years575.71%
TTM68.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM49.94%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM47.92%
Return on Capital
10 Years-45.84%
5 Years-60.09%
3 Years-50.69%
Last Year-11.16%
GERN Recent Earnings
Geron Corporation (GERN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 6, 2026EPS
$0.01
Est $0.03
+66.7%
Revenue
$52M
Est $51M
+2.5%
Q1 2026
Feb 25, 2026EPS
$0.03
Est $0.03
+0.0%
Revenue
$48M
Est $50M
-4.8%
Q4 2025
Nov 5, 2025EPS
$0.03
Est $0.04
+18.2%
Revenue
$47M
Est $53M
-11.5%
Q3 2025
Aug 6, 2025EPS
$0.02
Est $0.03
+33.3%
Revenue
$49M
Est $47M
+3.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.01vs $0.03+66.7% | $52Mvs $51M+2.5% |
| Q1 2026 | Feb 25, 2026 | $0.03vs $0.03+0.0% | $48Mvs $50M-4.8% |
| Q4 2025 | Nov 5, 2025 | $0.03vs $0.04+18.2% | $47Mvs $53M-11.5% |
| Q3 2025 | Aug 6, 2025 | $0.02vs $0.03+33.3% | $49Mvs $47M+3.7% |
Based on last 12 quarters of dataView full earnings history →
GERN Peer Comparison
Geron Corporation (GERN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ALLO | 529.95M | 2.31 | -2.66 | -100% | -57.07% | 0.26 | ||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 |
Compare GERN vs Peers
Geron Corporation (GERN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GERN Income Statement
Geron Corporation (GERN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.06M | 1.07M | 460K | 253K | 1.39M | 596K | 237K | 76.99M | 183.88M | 196.12M |
| Revenue Growth % | -82.72% | 0.09% | -56.85% | -45% | 450.59% | -57.21% | -60.23% | 32386.92% | 138.83% | 68.64% |
| Cost of Goods Sold | 8.44M | 12.72M | 51.27M | 50.05M | 0 | 0 | 0 | 1.26M | 4.75M | 24.61M |
| COGS % of Revenue | 792.21% | 1193.53% | 11146.09% | 19783.4% | - | - | - | 1.63% | 2.58% | - |
| Gross Profit | -7.37M▲ 0% | -11.66M▼ 58.1% | -50.81M▼ 335.9% | -49.8M▲ 2.0% | 1.39M▲ 102.8% | 596K▼ 57.2% | 237K▼ 60.2% | 75.74M▲ 31857.0% | 179.14M▲ 136.5% | 119.67M▲ 0% |
| Gross Margin % | -692.21% | -1093.53% | -11046.09% | -19683.4% | 100% | 100% | 100% | 98.37% | 97.42% | 61.02% |
| Gross Profit Growth % | 13.61% | -58.13% | -335.89% | 1.99% | 102.8% | -57.21% | -60.23% | 31856.96% | 136.52% | - |
| Operating Expenses | 30.32M | 32.14M | 21.69M | 27.11M | 115.39M | 139.15M | 194.18M | 249.47M | 232.97M | 207.18M |
| OpEx % of Revenue | 2846.95% | 3014.92% | 4715.87% | 10717% | 8283.7% | 23346.64% | 81932.91% | 324.01% | 126.7% | - |
| Selling, General & Admin | 19.29M | 18.71M | 21.69M | 27.11M | 29.66M | 43.63M | 69.14M | 145.73M | 159.26M | 154.66M |
| SG&A % of Revenue | 1810.99% | 1754.88% | 4715.87% | 10717% | 2129.58% | 7320.13% | 29170.89% | 189.28% | 86.61% | - |
| Research & Development | 11.03M | 13.43M | 52.07M | 51.49M | 85.73M | 95.52M | 125.05M | 103.74M | 73.72M | 73.59M |
| R&D % of Revenue | 1035.96% | 1260.04% | 11320% | 20350.99% | 6154.13% | 16026.51% | 52762.03% | 134.74% | 40.09% | - |
| Other Operating Expenses | 0 | -154K | -52.07M | -51.49M | 0 | 0 | 0 | 0 | 0 | -1000K |
| Operating Income | -29.25M▲ 0% | -31.07M▼ 6.2% | -72.5M▼ 133.3% | -76.91M▼ 6.1% | -114M▼ 48.2% | -138.55M▼ 21.5% | -193.94M▼ 40.0% | -173.73M▲ 10.4% | -53.84M▲ 69.0% | -36.97M▲ 0% |
| Operating Margin % | -2746.95% | -2914.92% | -15761.96% | -30400.4% | -8183.7% | -23246.64% | -81832.91% | -225.64% | -29.28% | -18.85% |
| Operating Income Growth % | 4.54% | -6.21% | -133.34% | -6.08% | -48.22% | -21.54% | -39.98% | 10.42% | 69.01% | - |
| EBITDA | -29.18M | -31.01M | -72.44M | -76.75M | -113.22M | -137.68M | -192.91M | -172.51M | -52.63M | -36.26M |
| EBITDA Margin % | -2739.81% | -2909.38% | -15748.04% | -30337.94% | -8127.49% | -23101.01% | -81397.05% | -224.06% | -28.62% | -18.49% |
| EBITDA Growth % | 4.53% | -6.29% | -133.58% | -5.96% | -47.5% | -21.61% | -40.11% | 10.57% | 69.49% | 72.75% |
| D&A (Non-Cash Add-back) | 76K | 59K | 64K | 158K | 783K | 868K | 1.03M | 1.22M | 1.2M | 712K |
| EBIT | -29.25M | -27.02M | -72.5M | -76.91M | -112.37M | -135.02M | -175.81M | -156.07M | -53.13M | -41.49M |
| Net Interest Income | 1.42M | 3.25M | 4.22M | 1.07M | -3.21M | -4.35M | 9.84M | 1.1M | -14.54M | -11.49M |
| Interest Income | 1.42M | 3.25M | 4.22M | 1.83M | 527K | 2.53M | 18.15M | 19.61M | 18.12M | 16.38M |
| Interest Expense | 0 | 0 | 0 | 760K | 3.74M | 6.88M | 8.31M | 18.5M | 32.66M | 17.31M |
| Other Income/Expense | 1.34M | 4.06M | 3.96M | 1.3M | -2.11M | -3.35M | 9.82M | -840K | -31.95M | -32.62M |
| Pretax Income | -27.92M▲ 0% | -27.02M▲ 3.2% | -68.55M▼ 153.7% | -75.62M▼ 10.3% | -116.11M▼ 53.6% | -141.9M▼ 22.2% | -184.13M▼ 29.8% | -174.57M▲ 5.2% | -85.78M▲ 50.9% | -69.59M▲ 0% |
| Pretax Margin % | -2621.22% | -2534.43% | -14901.74% | -29888.14% | -8335.39% | -23808.89% | -77690.72% | -226.73% | -46.65% | -35.48% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -27.92M▲ 0% | -27.02M▲ 3.2% | -68.55M▼ 153.7% | -75.62M▼ 10.3% | -116.11M▼ 53.6% | -141.9M▼ 22.2% | -184.13M▼ 29.8% | -174.57M▲ 5.2% | -85.78M▲ 50.9% | -69.59M▲ 0% |
| Net Margin % | -2621.22% | -2534.43% | -14901.74% | -29888.14% | -8335.39% | -23808.89% | -77690.72% | -226.73% | -46.65% | -35.48% |
| Net Income Growth % | 5.49% | 3.22% | -153.72% | -10.31% | -53.55% | -22.21% | -29.76% | 5.19% | 50.86% | 49.94% |
| Net Income (Continuing) | -27.92M | -27.02M | -68.55M | -75.62M | -116.11M | -141.9M | -184.13M | -174.57M | -85.78M | -69.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.18▲ 0% | -0.15▲ 16.7% | -0.33▼ 120.0% | -0.28▲ 15.2% | -0.37▼ 32.1% | -0.37▲ 0.0% | -0.32▲ 13.5% | -0.27▲ 15.6% | -0.13▲ 51.9% | -0.10▲ 0% |
| EPS Growth % | 5.26% | 16.67% | -120% | 15.15% | -32.14% | 0% | 13.51% | 15.63% | 51.85% | 47.92% |
| EPS (Basic) | -0.18 | -0.15 | -0.33 | -0.28 | -0.37 | -0.37 | -0.32 | -0.27 | -0.13 | - |
| Diluted Shares Outstanding | 159.22M | 176.5M | 190.16M | 271.46M | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M | 669.38M |
| Basic Shares Outstanding | 159.22M | 176.5M | 190.16M | 271.46M | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M | 669.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GERN Balance Sheet
Geron Corporation (GERN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 95.97M | 166.06M | 141.61M | 199.86M | 187.21M | 180.25M | 341.35M | 490.99M | 520.27M | 498.53M |
| Cash & Short-Term Investments | 94.95M | 163.56M | 139.32M | 196.28M | 183.72M | 172.75M | 333.7M | 406.57M | 359.8M | 312.4M |
| Cash Only | 16.6M | 10.84M | 13.64M | 9.93M | 34.87M | 56.84M | 70.02M | 79.02M | 79.44M | 68.89M |
| Short-Term Investments | 78.35M | 152.71M | 125.68M | 186.35M | 148.85M | 115.9M | 263.68M | 327.55M | 280.36M | 243.51M |
| Accounts Receivable | 436K | 1.17M | 802K | 722K | 1.76M | 3.14M | 1.66M | 38.8M | 39.23M | 41.88M |
| Days Sales Outstanding | 149.43 | 399.93 | 636.37 | 1.04K | 461.95 | 1.93K | 2.55K | 183.93 | 77.86 | 72.51 |
| Inventory | -436K | -1.17M | 0 | 0 | 0 | 0 | 0 | 38.71M | 0 | 133.29M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 11.25K | - | 1.1K |
| Other Current Assets | 268K | 269K | 270K | 363K | 364K | 4.36M | 5.99M | 6.91M | 121.25M | 10.96M |
| Total Non-Current Assets | 14.34M | 19.23M | 23.91M | 70.87M | 38.83M | 10.33M | 52.73M | 102.79M | 50.27M | 2.96M |
| Property, Plant & Equipment | 102K | 59K | 2.9M | 5.95M | 5.38M | 4.94M | 4.73M | 4.19M | 884K | 2.96M |
| Fixed Asset Turnover | 10.44x | 18.07x | 0.16x | 0.04x | 0.26x | 0.12x | 0.05x | 18.37x | 208.01x | 72.19x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 14.24M | 18.58M | 19.65M | 63.39M | 28.65M | 0 | 43.3M | 94.52M | 41.29M | 123.09M |
| Other Non-Current Assets | 0 | 585K | 1.35M | 1.53M | 4.8M | 5.39M | 4.7M | 4.08M | 8.1M | 13.91M |
| Total Assets | 110.31M▲ 0% | 185.28M▲ 68.0% | 165.52M▼ 10.7% | 270.73M▲ 63.6% | 226.03M▼ 16.5% | 190.57M▼ 15.7% | 394.08M▲ 106.8% | 593.78M▲ 50.7% | 570.54M▼ 3.9% | 501.49M▲ 0% |
| Asset Turnover | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x | 0.13x | 0.32x | 0.36x |
| Asset Growth % | -15.31% | 67.96% | -10.67% | 63.57% | -16.51% | -15.69% | 106.78% | 50.68% | -3.91% | 36.31% |
| Total Current Liabilities | 6.52M | 7.55M | 28.16M | 30.94M | 45.52M | 76.69M | 108.07M | 88.3M | 111.54M | 73.57M |
| Accounts Payable | 503K | 982K | 1.18M | 6.92M | 6.69M | 10.19M | 6.16M | 8.6M | 11.26M | 12.72M |
| Days Payables Outstanding | 21.76 | 28.17 | 8.41 | 50.46 | - | - | - | 2.5K | 865.92 | 160.61 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 20.95M | 46.89M | 0 | 18.45M | 1.01M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.36M | 3.6M | 4.83M | 8.22M | 8.1M | 11.53M | 13.76M | 43.18M | 80.84M | 72.56M |
| Current Ratio | 14.73x | 21.99x | 5.03x | 6.46x | 4.11x | 2.35x | 3.16x | 5.56x | 4.66x | 4.66x |
| Quick Ratio | 14.80x | 22.15x | 5.03x | 6.46x | 4.11x | 2.35x | 3.16x | 5.12x | 4.66x | 4.66x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 8.94K | - | 1.02K |
| Total Non-Current Liabilities | 0 | 0 | 2.2M | 28.84M | 54.1M | 33.88M | 38.06M | 225.16M | 233.13M | 231.44M |
| Long-Term Debt | 0 | 0 | 0 | 24.04M | 49.83M | 30.21M | 35.05M | 118.48M | 231.68M | 1.23M |
| Capital Lease Obligations | 0 | 0 | 2.2M | 4.8M | 4.27M | 3.67M | 3.01M | 2.27M | 1.45M | 4.97M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 104.42M | 0 | 450.79M |
| Total Liabilities | 6.52M | 7.55M | 30.36M | 59.78M | 99.62M | 110.58M | 146.13M | 313.46M | 344.67M | 305.01M |
| Total Debt | 0 | 0 | 2.55M | 29.72M | 55M | 55.75M | 85.9M | 121.72M | 251.57M | 2.23M |
| Net Debt | -16.6M | -10.84M | -11.09M | 19.79M | 20.13M | -1.09M | 15.88M | 42.7M | 172.13M | -66.66M |
| Debt / Equity | - | - | 0.02x | 0.14x | 0.44x | 0.70x | 0.35x | 0.43x | 1.11x | 1.11x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.84x |
| Interest Coverage | - | - | - | -101.20x | -30.05x | -19.62x | -21.15x | -8.43x | -1.63x | -2.40x |
| Total Equity | 103.8M▲ 0% | 177.73M▲ 71.2% | 135.16M▼ 24.0% | 210.95M▲ 56.1% | 126.42M▼ 40.1% | 80M▼ 36.7% | 247.95M▲ 209.9% | 280.32M▲ 13.1% | 225.87M▼ 19.4% | 229.11M▲ 0% |
| Equity Growth % | -15.18% | 71.23% | -23.96% | 56.08% | -40.07% | -36.72% | 209.94% | 13.06% | -19.42% | -64.3% |
| Book Value per Share | 0.65 | 1.01 | 0.71 | 0.78 | 0.39 | 0.21 | 0.43 | 0.43 | 0.34 | 0.34 |
| Total Shareholders' Equity | 103.8M | 177.73M | 135.16M | 210.95M | 126.42M | 80M | 247.95M | 280.32M | 225.87M | 229.11M |
| Common Stock | 160K | 186K | 200K | 310K | 324K | 390K | 545K | 606K | 640K | 641K |
| Retained Earnings | -985.84M | -1.01B | -1.08B | -1.16B | -1.27B | -1.41B | -1.6B | -1.77B | -1.86B | -1.86B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -207K | -183K | 132K | 78K | -173K | -219K | 185K | 261K | 269K | -191K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GERN Cash Flow Statement
Geron Corporation (GERN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.56M | -21.01M | -43.83M | -66.65M | -95.56M | -127.38M | -167.74M | -218.62M | -111.04M | -111.04M |
| Operating CF Margin % | -1930.14% | -1970.83% | -9528.04% | -26344.66% | -6859.73% | -21372.32% | -70777.64% | -283.94% | -60.39% | - |
| Operating CF Growth % | -11.91% | -2.2% | -108.62% | -52.07% | -43.37% | -33.3% | -31.69% | -30.33% | 49.21% | 144.38% |
| Net Income | -27.92M | -27.02M | -68.55M | -75.62M | -116.11M | -141.9M | -184.13M | -174.57M | -85.78M | -69.59M |
| Depreciation & Amortization | 76K | 59K | 776K | 935K | 783K | 868K | 1.03M | 1.22M | 1.2M | 1.22M |
| Stock-Based Compensation | 8.14M | 6.37M | 6.08M | 6.89M | 8.08M | 8M | 19.35M | 31.32M | 88K | 11.73M |
| Deferred Taxes | 310K | -365K | -1.33M | 488K | 191K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 200K | 191K | 68K | 264K | 984K | 626K | -10.06M | -8.18M | 41.99M | -38.24M |
| Working Capital Changes | -1.37M | -245K | 19.13M | 383K | 10.52M | 5.03M | 6.06M | -68.41M | -68.54M | -33.37M |
| Change in Receivables | 39K | -528K | 366K | 80K | -1.04M | -1.38M | 1.49M | -36.89M | -377K | -9.92M |
| Change in Inventory | 0 | 0 | -366K | -80K | 1.04M | 1.38M | 0 | -37.97M | -77.92M | -77.06M |
| Change in Payables | 278K | 479K | 199K | 5.73M | -232K | 3.5M | -4.03M | 2.44M | 2.66M | 1.46M |
| Cash from Investing | 22.97M | -77.72M | 27.4M | -105.32M | 71.95M | 62.07M | -180.32M | -106M | 107.25M | 106.66M |
| Capital Expenditures | 0 | -16K | -413K | -401K | -207K | -431K | -830K | -680K | -49K | -333K |
| CapEx % of Revenue | - | 1.5% | 89.78% | 158.5% | 14.86% | 72.32% | 350.21% | 0.88% | 0.03% | - |
| Acquisitions | 0 | 0 | -27.81M | 339K | 1.59M | -1.23M | 179.49M | 0 | 0 | -64K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 22.97M | -77.7M | 27.81M | -339K | -1.59M | 1.23M | -179.49M | 0 | 0 | 64K |
| Cash from Financing | 1.11M | 92.97M | 19.5M | 168.35M | 48.56M | 87.26M | 362.02M | 334.37M | 2.27M | 4.44M |
| Debt Issued (Net) | 0 | 0 | 0 | 23.86M | 24.89M | 0 | 29.7M | 34.57M | 0 | 0 |
| Equity Issued (Net) | 1.06M | 86.02M | 19.3M | 144.26M | 20.39M | 69.92M | 213.34M | 140.73M | 2.27M | 2.01M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 51K | 6.95M | 204K | 224K | 3.28M | 17.35M | 118.98M | 159.08M | 0 | 2.42M |
| Net Change in Cash | 3.52M▲ 0% | -5.76M▼ 263.4% | 3.07M▲ 153.3% | -3.63M▼ 218.1% | 24.95M▲ 788.0% | 21.97M▼ 11.9% | 13.93M▼ 36.6% | 9.74M▼ 30.1% | -1.44M▼ 114.7% | -14.83M▲ 0% |
| Free Cash Flow | -20.56M▲ 0% | -21.02M▼ 2.3% | -44.24M▼ 110.4% | -67.05M▼ 51.6% | -95.76M▼ 42.8% | -127.81M▼ 33.5% | -168.57M▼ 31.9% | -219.3M▼ 30.1% | -111.09M▲ 49.3% | -126.3M▲ 0% |
| FCF Margin % | -1930.14% | -1972.33% | -9617.83% | -26503.16% | -6874.59% | -21444.63% | -71127.85% | -284.82% | -60.41% | -64.4% |
| FCF Growth % | -11.56% | -2.28% | -110.43% | -51.56% | -42.82% | -33.46% | -31.89% | -30.09% | 49.34% | 38.21% |
| FCF per Share | -0.13 | -0.12 | -0.23 | -0.25 | -0.29 | -0.34 | -0.30 | -0.34 | -0.17 | -0.17 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.78x | 0.64x | 0.88x | 0.82x | 0.90x | 0.91x | 1.25x | 1.29x | 1.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GERN Key Ratios
Geron Corporation (GERN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -24.69% | -19.19% | -43.82% | -43.7% | -68.84% | -137.49% | -112.29% | -66.09% | -33.89% | -28.9% |
| Return on Invested Capital (ROIC) | -22.33% | -18.34% | -37.38% | -32.52% | -45.32% | -92.18% | -84.88% | -44.41% | -11.2% | -11.2% |
| Gross Margin | -692.21% | -1093.53% | -11046.09% | -19683.4% | 100% | 100% | 100% | 98.37% | 97.42% | 61.02% |
| Net Margin | -2621.22% | -2534.43% | -14901.74% | -29888.14% | -8335.39% | -23808.89% | -77690.72% | -226.73% | -46.65% | -35.48% |
| Debt / Equity | - | - | 0.02x | 0.14x | 0.44x | 0.70x | 0.35x | 0.43x | 1.11x | 1.11x |
| Interest Coverage | - | - | - | -101.20x | -30.05x | -19.62x | -21.15x | -8.43x | -1.63x | -2.40x |
| FCF Conversion | 0.74x | 0.78x | 0.64x | 0.88x | 0.82x | 0.90x | 0.91x | 1.25x | 1.29x | 1.81x |
| Revenue Growth | -82.72% | 0.09% | -56.85% | -45% | 450.59% | -57.21% | -60.23% | 32386.92% | 138.83% | 68.64% |
GERN SEC Filings & Documents
Geron Corporation (GERN) SEC filings — annual & quarterly reports (10-K, 10-Q)
GERN Frequently Asked Questions
Geron Corporation (GERN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Geron Corporation (GERN) reported $196.1M in revenue for fiscal year 2025. This represents a 3600% increase from $5.3M in 1996.
Geron Corporation (GERN) grew revenue by 138.8% over the past year. This is strong growth.
Geron Corporation (GERN) reported a net loss of $69.6M for fiscal year 2025.
Dividend & Returns
Geron Corporation (GERN) has a return on equity (ROE) of -33.9%. Negative ROE indicates the company is unprofitable.
Geron Corporation (GERN) had negative free cash flow of $126.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More GERN
Geron Corporation (GERN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates